Business Combinations (Purchase Price Allocation and Other Disclosures) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 ABH	Sep. 30, 2011 ABH	Sep. 30, 2012 ABH	Sep. 30, 2011 ABH	Jun. 28, 2011 ABH	Sep. 30, 2012 FerroKin BioSciences Inc	Sep. 30, 2011 FerroKin BioSciences Inc	Sep. 30, 2012 FerroKin BioSciences Inc	Sep. 30, 2011 FerroKin BioSciences Inc	Apr. 02, 2012 FerroKin BioSciences Inc	Apr. 19, 2012 Pervasis Therapeutics Inc
Non-current assets:
Goodwill														$ 46.1	$ 2.0
IPR&D														166.0	24.3
Current liabilities:
Accounts payable and other current liabilities														6.6	0.2
Non-current liabilities:
Other non-current liabilities														46.2
Contingent consideration payable - maximum														225.0	169.5
Cash consideration paid									739.6					94.5	2.5
The acquisition date fair value of total consideration														159.3	26.1
Contingent consideration														64.8	23.6
Post acquisition revenues included in consolidated statement of income					33.7	50.0	134.9	52.0
Net income	227.2	192.9	703.4	609.7
Post acquisition pre-tax losses included in consolidated statement of income					(27.6)	(5.4)	(53.2)	(12.0)		(0.4)	0	(2.8)	0
Amortization of intangible assets					10.5	9.8	30.3	10.0
Integration and acquisition costs	$ 2.7	$ 5.3	$ 15.1	$ 7.9	$ 1.1	$ 3.6	$ 9.0	$ 10.5		$ 0.4	$ 0	$ 2.8	$ 0
Percentage of voting interests acquired									100.00%					100.00%